Infant and child microbiota: current status and directions for future research
PD Browne, MB Van der Waal, E Claassen - Microbiota in health and …, 2017 - brill.com
A balanced microbial composition is essential in maintaining health during infancy and
childhood (0-12 years). Alterations in microbial communities may increase a child’s susceptibility …
childhood (0-12 years). Alterations in microbial communities may increase a child’s susceptibility …
[CITAAT][C] Naar een gezonde veehouderij in 2015. 5. Technologie en dierziekten: drama of draad van Ariadne?
E Claassen - 1997 - library.wur.nl
Naar een gezonde veehouderij in 2015. 5. Technologie en dierziekten: drama of draad van
Ariadne? wur logo Staff Publications Staff Publications external user (warning warning ) Log in …
Ariadne? wur logo Staff Publications Staff Publications external user (warning warning ) Log in …
[CITAAT][C] Safety of probiotics in infants and children
M Nieuwboer, PD Browne, E Claassen - 2017 - repository.ubn.ru.nl
Since the PROPATRIA-trial in 2008, probiotics have been placed under scrutiny and concerns
have been raised regarding the safety of administration of live microorganisms. When …
have been raised regarding the safety of administration of live microorganisms. When …
Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 vaccines and therapeutics Task force members
To date, just over 100 million COVID-19 immunizations have been administered, led by the
United States accounting for more than onethird (35 million), followed by China (24 million) …
United States accounting for more than onethird (35 million), followed by China (24 million) …
COVID-19 mRNA vaccines: Platforms and current developments
GT Szabó, AJ Mahiny, I Vlatkovic - Molecular Therapy, 2022 - cell.com
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in the …
agent in a preclinical study nearly 30 years ago, numerous advances have been made in the …
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that
protect against severe disease and preferably drive herd immunity. Regulators in numerous …
protect against severe disease and preferably drive herd immunity. Regulators in numerous …
Risk in vaccine research and development quantified
ES Pronker, TC Weenen, H Commandeur… - PloS one, 2013 - journals.plos.org
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently,
a productivity gap affects the pharmaceutical industry. The productivity gap describes the …
a productivity gap affects the pharmaceutical industry. The productivity gap describes the …
[CITAAT][C] Claassen EHJHM and Osterhaus ADME (2013). Risk in Vaccine Research and Development Quantified
ES Pronker, TC Weenen, H Commandeur - PLoS One
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis …
FG Sandmann, NG Davies, A Vassall… - The Lancet infectious …, 2021 - thelancet.com
Background In response to the COVID-19 pandemic, the UK first adopted physical distancing
measures in March, 2020. Vaccines against SARS-CoV-2 became available in December, …
measures in March, 2020. Vaccines against SARS-CoV-2 became available in December, …
The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline
I Frost, H Sati, P Garcia-Vello… - The Lancet …, 2023 - thelancet.com
Vaccines can be highly effective tools in combating antimicrobial resistance as they reduce
infections caused by antibiotic-resistant bacteria and antibiotic consumption associated with …
infections caused by antibiotic-resistant bacteria and antibiotic consumption associated with …